KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study.

Sudeep Gupta, Ghanashyam Biswas, Suresh Babu, Tanveer M Maksud, Kuntegowdennahalli C Lakshmaiah, Jayanti G Patel, Gopal Raja, Rakesh R Boya, Pramod Patil, Kakali Choudhury, Shailesh A Bondarde, Rakesh S Neve, Guruprasad Bhat, Gopichand Mamillapalli, Apurva A Patel, Piyush Patel, Nisarg Joshi, Vinay Bajaj, Mujtaba A Khan

Breast 60 147-154

PMID34624757
PMCIDPMC8503662
DOI10.1016/j.breast.2021.09.012
发表日期2021-10-08
入排依据:The study is an oncology, human, randomized, Phase 2/3 trial with a drug-containing intervention and reports original results. However, the primary and reported efficacy endpoints are objective response rate (BOR) and disease control rate (DCR), which are categorical outcomes. There is no mention of survival endpoints (OS, PFS, DFS, etc.), Kaplan-Meier survival curves, or hazard ratios in the provided abstract. Therefore, it lacks the required time-to-event efficacy endpoint for inclusion in this KM-digitization cohort.
摘要

摘要

AIM: To evaluate pharmacokinetics, efficacy and safety of fixed-dose combination (FDC) of oral capecitabine + cyclophosphamide in metastatic breast cancer (MBC) patients progressing after anthracycline and/or taxane chemotherapy. METHODS: In this prospective, adaptive, phase-2/3, open-label study (CTRI/2014/12/005234), patients were randomized (1:1:1) to three FDC doses (doses/day: D1, capecitabine + cyclophosphamide 1400 mg + 60 mg; D2, 1800 mg + 80 mg; D3, 2200 mg + 100 mg) for 14 days, in 21-day cycles. In Part-I, multiple-dose pharmacokinetics and optimal dose(s) were evaluated with futility analysis. Group(s) with <3 responders based on best overall response rate (BOR, complete response [CR]+partial response [PR]), were discontinued. Efficacy (BOR, disease control rates [DCR; CR + PR + stable disease]) and safety of optimal dose(s) were evaluated in Part-II. RESULTS: Of 66 patients (n = 22/group) in Part-I, pharmacokinetics (D1 = 7/22, D2 = 9/22, D3 = 8/22) showed dose-proportionality for cyclophosphamide and greater than dose-proportionality for capecitabine. Modified intent-to-treat (mITT) analysis showed BOR of 7.14% (1/14) in D1 (discontinued), and 22.22% (4/18) each in D2 and D3, respectively. In Part-II, 50 additional patients were randomized in D2 and D3 (n = 144; total 72 [22 + 50] patients/group). mITT analysis in D2 (n = 54) and D3 (n = 58) showed BOR of 29.63% (16/54, 95%CI: 17.45-41.81%) and 22.41% (13/58, 95%CI: 11.68-33.15%), respectively. DCR in D2 and D3 were 87.04% (47/54, 95%CI: 78.08-96.00%) and 82.76% (48/58; 95%CI: 73.04-92.48%) after 3 and 57.41% (31/54; 95%CI: 52.41-79.50%) and 50.00% (29/58; 95%CI: 40.40-67.00%), after 6-cycles, respectively. Hand-foot syndrome (16.67%), vomiting (9.72%) in D2, and hand-foot syndrome (18.06%), asthenia (15.28%) in D3 were most-common adverse events. CONCLUSION: FDC of capecitabine + cyclophosphamide (1800 + 80 mg/day) showed high disease control rates and good safety profile in MBC patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。